Background. Fibrin generation during and after therapy with alteplase may depend on the level of concomitant anticoagulation. The hypothesis that fibrinopeptide A (FPA) levels, as markers of ongoing in vivo fibrin formation, correlate with the angiographic and clinical outcome of thrombolysis is tested.
It is well established that heparin therapy alone is associated with a significant reduction of left ventricular thrombosis, stroke, deep vein thrombosis, pulmonary embolism, reinfarction, and death in patients with acute myocardial infarction. 8-1' In experimental animal models of arterial12-14 or venous14'15 thrombosis, thrombolysis induced with alteplase (recombinant tissue-type plasminogen activator, rt-PA) is enhanced by pretreatment'12"3 or concomitant infusion'4 of heparin or heparin fragments.'1 The role of early intravenous heparin for sustained coronary artery patency after alteplase administration to patients with acute myocardial infarction has been investigated in several recent studies. 16-'9 Despite similar initial (90 minutes) patency rates with or without concomitant heparin use,16 significantly higher patency rates in the heparin-treated groups were observed at 18 hours,'8 48 hours,17 and 84 hours,'9 with18"19 or without17 the addition of aspirin.
The potential role of intravenous heparin given concomitantly with streptokinase or alteplase therapy had earlier been suggested with the demonstration of fibrinopeptide A (FPA) generation during infusion of thrombolytic agents20-22 and its rapid decrease following anticoagulation.22-3 Moreover, it was suggested that persistently high or reincreasing FPA plasma levels despite adequate anticoagulation might correlate with coronary artery reocclusion after alteplase22 or streptokinase. 20 See p 1205
The sixth trial of the European Cooperative Study Group (ECSG), which randomized 652 patients with acute myocardial infarction treated with alteplase and aspirin to either concomitant intravenous heparin or placebo, demonstrated that allocation to heparin is associated with a higher patency rate at 48-120 hours (83% versus 75%, p=0.02. 19 The present study, performed in a representative subgroup (n=334) of the ECSG trial, prospectively tests the hypothesis that plasma FPA levels depend on the intensity of anticoagulation and may be useful markers of coronary artery patency after alteplase treatment. 22 To this end, sequential FPA levels were correlated with the assignment to treatment, with the intensity of anticoagulation reflected by serial activated partial thromboplastin times (aPTIT), with subsequent angiographic coronary patency, with recurrent ischemic events, and with the echocardiographic presence of left ventricular thrombosis.
Methods

Patient Selection and Treatment
The present investigation represents an ancillary study to the double-blind sixth trial of the ECSG, comparing immediate intravenous heparin versus placebo in patients with acute myocardial infarction treated with alteplase and aspirin. 19 The first 400 of a total of 652 patients that were entered into the study were scheduled for serial blood sampling. Frozen plasma samples of 349 patients were available for analysis of FPA plasma levels. Of these, 15 patients were excluded for having either received a second dose of alteplase within 36 hours (nine patients), undergone early angiography within the first 36 hours during which the plasma samples were collected (four patients), or both (two patients). Thus, for hemostasis analysis, 334 patients constitute the data base of the present study. The entry criteria, randomization procedure, and administration scheme of alteplase and aspirin are reported in detail elsewhere. 19 Patients randomized to heparin were given the drug as an intravenous bolus of 5,000 units immediately before the start of alteplase, followed by an infusion of 1,000 units per hour. This dose remained unchanged until angiography unless potentially drug-related complications or a pertinent indication for anticoagulation (e.g., left ventricular thrombi) occurred; after angiography (primary end point of the study), investigators were free to discontinue the heparin administration. Placebo (dilute albumin solution) was prepared in vials identical to heparin and given in the same way to patients randomized to placebo.
Coronary Angiography
Coronary angiography was performed in 321 of the constitute the primary data base of the present study. It was not available because of death, complications, or patient refusal in nine heparin-treated patients and in 19 placebo-group patients. The patency of the infarctrelated vessel was centrally assessed by a panel of five observers blinded to the treatment allocation. Results are reported in terms of TIMI grades.24 Echocardiography Two-dimensional echocardiography of sufficient quality to identify left ventricular thrombi was obtained 48 to 120 hours after the start of thrombolytic therapy in 317 of the 334 patients (95%). Videotapes were analyzed centrally by observers unaware of the treatment allocation.
Recurrent Ischemia and Reinfarction
Clinical, electrocardiographic, and enzymatic evidence of recurrent ischemia and reinfarction was divided into events occurring between treatment allocation and angiography and between angiography and hospital discharge. Recurrent ischemic events were classified as reinfarction (recurrent enzyme rise), unstable angina (recurrent ST segment elevation without enzyme rise), and other chest pain. Repeated administration of alteplase for reinfarction was allowed by the protocol, but these patients (n=9) are excluded from the laboratory analysis (FPA and aPTT).
Blood Sampling and Handling
Blood was collected at baseline (before treatment allocation) and 45 minutes, 3 hours (end of alteplase infusion), 12 hours, 24 hours, and 36 hours after initiation of therapy. Blood collection tubes containing either citrate (final concentration 0.01 mol/l) alone or citrate and D-phenyl-prolyl-arginine-chloromethylketone (PPACK, final concentration 0.002 mmol/l), which inhibits thrombin25 and alteplase26 efficiently, were provided for each sampling time point. Heparin, therefore, did not affect the FPA assay. Venous blood was collected from a free-flowing needle and without tourniquet, if possible. Sampling from an indwelling catheter was allowed after the first 10 ml of blood was discarded. The chilled tubes were centrifuged within 20 minutes at 4°C and 2,000g for 10-20 minutes, and the platelet-poor plasma was stored at -20°C.
Laboratory Analyses
All laboratory analyses were performed at the Center for Thrombosis and Vascular Research in a blinded manner.
FPA was determined in PPACK-inhibited plasma samples by a radioimmunoassay27 with polyclonal antibodies (Imco, Stockholm). Crossreacting fibrinogen was eliminated from plasma by bentonite adsorption before use in the assay. Free antigen was separated from bound antigen by use of an immobilized second goat antirabbit antibody (Immunobeads, Bio-Rad Laboratories, Richmond, Calif.). All samples yielding FPA values >300 ng/ml were reanalyzed after repeated adsorption of fibrinogen by bentonite, with similar values on reanalysis in each case. aPTTs were determined in plasma samples collected on citrate with automated coagulation equipment (ACL, Instrumentation Laboratory, Milan, Italy). Ade-349 patients (92%) and in 306 of the 334 patients whO quate anticoagulation was defined as no aPTT <200% of the baseline value measured at 3, 12, 24, and 36 hours. At least two of these four samples in addition to the baseline sample had to be available for analysis, which excluded 55 patients from the assessment of adequacy of anticoagulation but not from correlations between aPTT and FPA. In the remaining 279 patients, a complete set of four samples was obtained in 78%, three samples in 17%, and two samples in 5%. In order to test residual PPACK activity, thrombin times were also determined in 50 samples collected at baseline (before heparin or placebo treatment) on PPACK samples. They were all prolonged to at least 40 seconds over a control value of 20 seconds.
Statistical Analysis
Descriptive statistics of the data include median values and 10th to 90th percentiles. Mann-Whitney U tests were used to compare FPA values (which did not follow a Gaussian distribution) between the groups at each time point. For comparison of sequential FPA values, the data were logarithmically transformed before being tested by repeated-measurements ANOVA (spss program). For the main analyses, which compared FPA plasma levels with assignment to treatment, adequacy of anticoagulation, and vessel patency, a=0.05 was used as level of significance. Other analyses were performed as post hoc exploratory data analysis. No multiple comparison adjustments were made. FPA and aPTT were correlated at each time point by linear regression and by Spearman's rank correlation. Discrete variables, such as threshold FPA plasma levels, were tested by Fisher's exact test, and their clinical usefulness was expressed in terms of sensitivity and specificity.
The statistical interpretation of the correlation between FPA levels and vessel patency is limited by the small number of patients in the subgroups with occluded vessels,28 by missing data (for the repeatedmeasurements ANOVA), and by the range of FPA values, which is non-Gaussian. The comparison of threshold FPA levels was done as a post hoc analysis.
Results
Baseline Characteristics of the Patients
Serial blood samples of 334 patients, 168 allocated to concomitant heparin and 166 allocated to placebo, were analyzed. The baseline characteristics of the patients in these two groups were well balanced and indistinguishable from those of the total population of the ECSG-6 trial described elsewhere. 19 Plasma Fibrinopeptide A Levels Before, During, and After Alteplase Infusion In total, 1,676 plasma samples (5.2 per patient) were suitable for FPA assays. The results are summarized in Figure 1 . Median FPA plasma levels (with their 10th to 90th percentiles) at baseline were 21 ng/ml (2-390 ng/ml) in placebo-allocated patients (n = 166) and 18 ng/ml (2-210 ng/ml) in heparin-allocated patients (n=168) (p=NS). A significant further increase to 49 ng/ml (15-580 ng/ml) was observed after 45 minutes of alteplase infusion in placebo-assigned patients, followed by persistently high FPA levels at 3 hours (34 ng/ml, 4-320 ng/ml), 12 hours (27 ng/ml, 2-240 ng/ml), 24 hours (29 ng/ml, 2-430 ng/ml), and 36 hours (30 ng/ml, 3-390 ng/ml). In contrast, FPA levels in patients allocated to alteplase and concomitant heparin fell to 6 (1-110), 5 (1-75), 5 (1-60), 7 (1-100), and 10 (1-170) ng/ml at 45 minutes, 3 hours, 12 hours, 24 hours, and 36 hours, respectively (p<0.0001 between groups for each time point). Serial FPA plasma levels also reflected the quality of anticoagulation, as summarized in Figure 2 . Adequate anticoagulation in heparin-assigned patients, defined as no aPTT <200% of baseline value at 3, 12, 24, and 36 hours (n=48 patients), was associated with normal median FPA levels of 4 (1-32), 3 (1-24), 2 (1-10), 2 (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) , and 2 (1-15) ng/ml at 45 minutes, 3 hours, 12 hours, 24 hours, and 36 hours, respectively. Patients assigned to heparin but not adequately anticoagulated (n= 102) had significantly higher FPA levels of 12 (2-80), 16 (2-240), and 15 (1-240) ng/ml at 12, 24, and 36 hours, respectively (p<0.001 versus adequately anticoagulated patients at each time point). Linear regression revealed no significant correlation between FPA values and corresponding aPTT value, but Spearman's rank correlation between FPA and aPTT was significant in heparin-treated patients at 24 hours (p=0.028) and 36 hours (p=0.04). Table 1 and Figure 3 summarize the results of an analysis of FPA plasma levels according to treatment allocation and according to infarct-related coronary artery patency at 48-120 hours. Coronary artery pa- tency, classified by the TIMI criteria24 in the 334 patients of the present study, was 72% in those allocated to placebo and 81% in those allocated to heparin (p=0.08). Including 15 patients with early angiography or repeated alteplase treatment within 36 hours in whom blood samples for hemostasis analysis were also obtained, coronary artery patency was higher in the heparin-allocated patients than in the placebo-allocated patients (82% versus 69%, n=349, p=0.015). These findings are in agreement with the results obtained in the total patient population of the ECSG-6 trial. 19 Median FPA levels tended to be lower at all time points in heparin-allocated patients with subsequently determined patent infarct-related vessels (5, 4, 4, 5, and 9 ng/ml, n=129) than in heparinallocated patients with occluded arteries (8, 8, 11, 21 , and 15 ng/ml, n=30), but the difference was statistically significant only at 24 hours (p=0.04) and not overall (p=0.2 by repeated-measurements ANOVA in 91 versus 21 patients with a complete set of data). In placebo-assigned patients, median FPA levels did not correlate with vessel patency (p=0.89). Threshold Plasma Fibrinopeptide A Levels as a Marker of Vessel Patency and Recurrent Ischemia Several FPA threshold plasma levels (20, 50, 100, and 200 ng/ml) at different time points (3, 12, 24 , and 36 hours) were tested for their predictive value for coronary patency at 48-120 hours or for a recurrent ischemic event. The best results were obtained in heparintreated patients with an FPA threshold level of 50 ng/ml at 24 hours (Table 2 ). FPA levels <50 ng/ml at 24 hours were associated with a significantly higher patency rate than FPA levels >50 ng/ml at 24 hours (88% versus 55%, p<0.0001). The sensitivity and specificity of an FPA plasma level >50 ng/ml at 24 hours as a predictor of a subsequently occluded infarct-related artery were 48% and 86%, respectively. In the subgroup of adequately anticoagulated patients, these values increased to 67% and 97%, respectively, but the small number of adequately anticoagulated patients with occluded coronary arteries (three of 48) casts doubt on the validity of this analysis. In placebo-treated patients, no significant correlation between plasma FPA levels and coronary patency was observed. (3-390) 37 12 (2-250) 45 min 113 5
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(1-170) 27 15 ( Recurrent clinical ischemic events were registered between the end of the alteplase infusion and angiography as either reinfarction, unstable angina, or other chest pain in 18% of placeboversus 11% of heparinassigned patients (n=349, including 15 patients with early angiography or given a second dose of alteplase for reinfarction, p=0.13). Adequate anticoagulation was not associated with better protection against recurrent ischemia than was inadequate anticoagulation. Left ventricular mural thrombi were detected by two-dimensional echocardiography in nine patients (8%) assigned to placebo and in six patients (4%) allocated to heparin (p=0.39). Threshold plasma levels of FPA did not correlate with either recurrent ischemic events or left ventricular thrombosis.
Discussion
The importance of anticoagulation as conjunctive treatment during thrombolytic therapy with alteplase has been underrated. Similar early (90 minutes) coronary patency during alteplase infusion with or without heparin16 and the fear of bleeding complications have contributed to defer anticoagulation until 12 hours after thrombolytic therapy in the Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI)-2 and in the International Study Group rt-PA/ streptokinase mortality trials.5
The present study was performed in a representative subgroup (n=334) of the sixth trial of the ECSG,19 in which patients with acute myocardial infarction treated with alteplase and aspirin were randomized to either concomitant intravenous heparin or placebo. It prospectively tests the hypothesis that FPA plasma levels after thrombolytic treatment with alteplase correlate with heparin treatment, subsequent coronary patency, recurrent ischemic events, and left ventricular thrombosis.
In patients with acute myocardial infarction given intravenous heparin in addition to alteplase and aspirin, a higher patency rate, expressed as TIMI grade 2 or 3 perfusion,24 is observed: 81% versus 72% in the 334 patients of the present study (p=0.08). These results are in line with the overall angiographic analysis of the ECSG-6 trial (TIMI grade 2 or 3 in 221 of 265 [83%] of heparin-assigned patients versus 189 of 253 [75%] of placebo-assigned patients, p=0.02) 19 and with the results of two smaller prospective studies that found significantly lower patency rates at 18 hours18 and 48 hours17 in patients treated with alteplase without heparin. Early recurrent ischemic events, reinfarction, and unstable angina (11% versus 18%, p=0.13) as well as left ventricular thrombosis detected by two-dimensional echocardiography (4% versus 8%, p=0.39), were not significantly less frequent in heparin-treated patients.
A fixed dose of intravenous heparin (5,000 units as a bolus followed by 1,000 units/hr as an infusion) resulted in persistently doubled aPTTs over 36 hours, defined as adequate anticoagulation, in only one third of the patients assigned to heparin. Optimal anticoagulation, therefore, warrants individual titration of the heparin dose administered.
Baseline median FPA plasma levels in the present study were 10-fold above normal, which confirms a previously reported intense hypercoagulable state in the early hours of myocardial infarction.29-32 Median FPA levels 45 minutes after initiation of alteplase were 49 ng/ml in the absence of concomitant heparin and 6 ng/ml in the presence of heparin. These findings are compatible with the hypothesis that thrombin activity is generated during alteplase infusion, as previously implied from FPA measurements before and after heparin infusion. 22, 23 In the absence of heparin, thrombin activity persists for at least 36 hours, whereas in adequately anticoagulated patients, plasma FPA levels are quickly reduced to normal levels. As expected, aspirin, given together with alteplase to all patients in this study, does not inhibit thrombin-induced platelet aggregation. 33 Although FPA plasma levels are strongly associated with the assignment to heparin (p<0.0001) as well as with the quality of anticoagulation during 36 hours (p<0.001), the correlation with subsequent vessel patency is significant only at 24 hours (p =0.04). This might in part be a result of the small number of patients in the subgroups with occluded vessels. On the other hand, multiple comparisons at different time points increase the possibility that a difference is a result of chance. In heparin-treated patients, an FPA threshold level of 50 ng/ml at 24 hours is a relatively specific marker of subsequent vessel occlusion (86%), but it lacks sensitivity (48%). FPA plasma levels do not correlate with clinically apparent recurrent ischemic events (reinfarction or unstable angina) or with left ventricular thrombosis in two-dimensional echocardiography. Whether thrombin/antithrombin III (TAT-) complex levels, alternatively proposed as reocclusion marker in small patient groups,34,35 are clinically more useful remains to be shown.
Monitoring of fibrin generation by plasma FPA levels deserves a few remarks. First, thrombin specifically cleaves FPA (Aal-16) from the aminotermini of fibrinogen's a-chain and initiates fibrin generation.36 FPA plasma levels represent a very sensitive marker of thrombin activity in vivo; adequate thrombin inhibition by heparin results in a rapid decrease of FPA levels.22,23,37,38 Systemic FPA plasma levels, however, cannot be expected to reflect only coronary thrombosis. 31 Indeed, generalized fibrin generation may take place on damaged endothelium of arteries or veins in ischemic territories. Second, plasmin cleaves larger peptides from fibrinogen that contain the FPA sequence, that may crossreact in the FPA assay, or that may release FPA after subsequent cleavage by thrombin. This reaction might explain the high FPA values measured during streptokinase therapy. 20 Finally, alteplase itself may release low amounts of fibrinopeptides (mainly fibrinopeptide B) from fibrinogen39; this potentially direct prothrombotic property of alteplase, however, would not be inhibited by heparin.2 FPA plasma levels, therefore, most likely reflect overall intravascular thrombin activity in patients treated with alteplase.
The relative importance of early anticoagulation for the thrombolytic efficacy of drugs that induce extensive fibrinogen consumption, such as streptokinase or urokinase, is less well established. Earlier nonrandomized studies with streptokinase have suggested that concomitant use of heparin accelerates reperfusion40 and that discontinuation of heparin predisposes to ischemic events. 41 The experimental observation that defibrinogenating agents enhance thrombolysis with alteplase to an extent comparable to heparin12,13 suggests that anticoagulation may be less important for the efficacy of thrombolysis in the presence of low fibrinogen levels.
In conclusion, the present study shows that during and after thrombolytic therapy with alteplase in patients with acute myocardial infarction, systemic thrombin activity, as reflected by FPA plasma levels, is greatly enhanced in the absence of concomitant heparin anticoagulation; it decreases in patients treated with heparin and may be normalized if anticoagulation is adequate and sustained. The importance of concomitant and intense anticoagulation for late coronary patency after alteplase therapy is confirmed. Optimal anticoagulation warrants individual titration of the heparin dose. Threshold levels of FPA may be useful in anticoagulated patients as a marker of arterial patency following thrombolytic treatment. FPA plasma levels, however, do not correlate with clinically apparent recurrent ischemia or with left ventricular thrombosis.
